Top

Published in:

01-06-2013 | Review

Influence of Bariatric Surgery on the Use and Pharmacokinetics of Some Major Drug Classes

Authors: Jan Peter Yska, Susanne van der Linde, Véronique V. Tapper, Jan A. Apers, Marloes Emous, Erik R. Totté, Bob Wilffert, Eric N. van Roon

Published in: Obesity Surgery | Issue 6/2013

Abstract

The purpose of this review is to evaluate the influence of bariatric surgery on the use and pharmacokinetics of some frequently used drugs. A PubMed literature search was conducted. Literature was included on influence of bariatric surgery on pharmacoepidemiology and pharmacokinetics. Drug classes to be searched for were antidepressants, antidiabetics, statins, antihypertensive agents, corticosteroids, oral contraceptives, and thyroid drugs. A reduction in the use of medication by patients after bariatric surgery has been reported for various drug classes. Very few studies have been published on the influence of bariatric surgery on the pharmacokinetics of drugs. After bariatric surgery, theoretically, reduced drug absorption may occur. Correct dosing and choosing the right dosage form for drugs used by patients after bariatric surgery are necessary for optimal pharmacotherapy. Therefore, more clinical studies are needed on the influence of bariatric surgery on the pharmacokinetics of major drugs.

Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRef

Leff DR, Heath D. Surgery for obesity in adulthood. Br Med J. 2009;339:740–6.CrossRef

Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: An 18-year report from the International Bariatric Surgery Registry. Am J Surg. 2006;192:657–62.PubMedCrossRef

Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical complications. Obes Rev. 2010;11:41–50.PubMedCrossRef

MacGregor AMC, Boggs L. Drug distribution in obesity and following bariatric surgery: A literature review. Obes Surg. 1996;6:17–27.PubMedCrossRef

Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract. 2003;18:131–5.PubMedCrossRef

Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63:1852–57.PubMedCrossRef

Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg. 2009;19:1646–56.PubMedCrossRef

Cunningham JL, Merrell CC, Sarr M, et al. Investigation of antidepressant medication usage after bariatric surgery. Obes Surg. 2012;22:530–5.PubMedCrossRef

10.

Voelker M, Foster TG. Nursing challenges in the administration of oral antidepressant medications in gastric bypass patients. J Perianesth Nurs. 2007;22:108–24.PubMedCrossRef

11.

Seaman JS, Bowers SP, Dixon P, et al. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005;46:250–3.PubMedCrossRef

12.

Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8:62–6.PubMedCrossRef

13.

Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169:256–63.PubMedCrossRef

14.

Scheen A-J, De Flines J, De Roover A, et al. Bariatric surgery in patients with type 2 diabetes: Benefits, risks, indications and perspectives. Diabetes Metab. 2009;35:537–43.PubMedCrossRef

15.

Renard E. Bariatric surgery in patients with late-stage type 2 diabetes: Expected beneficial effects on risk ratio and outcomes. Diabetes Metab. 2009;35:564–8.PubMedCrossRef

16.

Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and β-cell function in type 2 diabetes. Diabetes Care. 2009;32:514–20.PubMedCrossRef

17.

Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef

18.

Dixon JB, Le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet. 2012;379:2300–11.PubMedCrossRef

19.

Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122–31.PubMedCrossRef

20.

Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84.PubMed

21.

Brancatisano A, Wahlroos S, Matthews S, et al. Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. Surg Obes Relat Dis. 2008;4:423–9.PubMedCrossRef

22.

Dorman RB, Serrot FJ, Miller CJ, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg. 2012;255:287–93.PubMedCrossRef

23.

Pournaras DJ, Aasheim ET, Søvik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012;99:100–3.PubMedCrossRef

24.

Jurowich C, Thalheimer A, Hartmann D, et al. Improvement of type 2 diabetes mellitus (T2DM) after bariatric surgery—who fails in the early postoperative course? Obes Surg. 2012;22:1521–6.PubMedCrossRef

25.

Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.PubMedCrossRef

26.

Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. NJEM. 2012;366:1577–85.CrossRef

27.

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. NJEM. 2012;366:1567–76.CrossRef

28.

Malone M, Alger-Mayer SA. Medication use patterns after gastric bypass surgery for weight management. Ann Pharmacother. 2005;39:637–42.PubMedCrossRef

29.

Segato G, Busetto L, De Luca M, et al. Weight loss and changes in use of antidiabetic medication in obese type 2 diabetics after laparoscopic gastric banding. Surg Obes Rel Dis. 2010;6:132–7.CrossRef

30.

Maciejewski ML, Livinston EH, Kahwati LC, et al. Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. Surg Obes Rel Dis. 2010;6:601–7.CrossRef

31.

Nocca D, Guillaume F, Noel P, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21:738–43.PubMedCrossRef

32.

Narbro K, Ågren G, Jonsson E, et al. Pharmaceutical costs in obese individuals. Comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: The SOS intervention study. Arch Intern Med. 2002;162:2061–9.PubMedCrossRef

33.

Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric surgery: Shredding the monetary weight of prescription costs in the managed care arena. Obes Surg. 2004;14:725–30.PubMedCrossRef

34.

Nguyen NT, Varela E, Sabio A, et al. Reduction in prescription medication costs after laparoscopic gastric bypass. Am Surg. 2006;72:853–6.PubMed

35.

Makary MA, Clarke JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg. 2010;145:726–31.PubMedCrossRef

36.

Klein S, Ghosh A, Cremieux PY, et al. Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI ≥ 35 kg/m². Obesity. 2011;19:581–7.PubMedCrossRef

37.

Ghiassi S, Morton J, Bellatore N, et al. Short-term medication cost savings for treating hypertension and diabetes after gastric bypass. Surg Obes Relat Dis. 2012;8:269–74.PubMedCrossRef

38.

Neovius M, Narbro K, Keating C, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308:1132–41.PubMedCrossRef

39.

Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34:1295–300.PubMedCrossRef

40.

Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009;86:311–8.PubMedCrossRef

41.

Skottheim IB, Jakobsen GS, Stormark K, et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin Pharmacol Ther. 2010;87:699–705.PubMedCrossRef

42.

Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005;19:117–25.PubMedCrossRef

43.

Donadelli SP, Salgado W, Marchini JS, et al. Change in predicted 10-year cardiovascular risk following Roux-en-Y gastric bypass surgery: Who benefits? Obes Surg. 2011;21:569–73.PubMedCrossRef

44.

Hodo DM, Waller JL, Martindale RG, et al. Medication use after bariatric surgery in a managed care cohort. Surg Obes Rel Dis. 2008;4:601–7.CrossRef

45.

Crémieux PY, Ledoux S, Clerici C, et al. The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg. 2010;20:861–70.PubMedCrossRef

46.

Wójcicki J, Wojciechowski G, Wójcicki M, et al. Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: A comparative study. Eur J Clin Pharmacol. 2000;56:75–9.PubMedCrossRef

47.

Valdivieso A, Calvo R, Gonzalez JP, et al. Influence of several surgical techniques in peptic ulcer disease on the oral kinetic of a basic drug. Acta Chir Belg. 1993;93:88–91.PubMed

48.

Reddy RC, Baptist AP, Fan Z, et al. The effects of bariatric surgery on asthma severity. Obes Surg. 2011;21:200–6.PubMedCrossRef

49.

Sikka N, Wegienka G, Havstad S, et al. Respiratory medication prescriptions before and after bariatric surgery. Ann Allergy Asthma Immunol. 2010;104:326–30.PubMedCrossRef

50.

Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril. 2009;92:1501–8.PubMedCrossRef

51.

Gerrits EG, Ceulemans R, Van Hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg. 2003;13:378–82.PubMedCrossRef

52.

Merhi ZO. Challenging oral contraception after weight loss by bariatric surgery. Gynecol Obstet Invest. 2007;64:100–2.PubMedCrossRef

53.

Paulen ME, Zapata LB, Cansino C, et al. Contraceptive use among women with a history of bariatric surgery: A systematic review. Contraception. 2010;82:86–94.PubMedCrossRef

54.

Raftopoulos Y, Gagné DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509–13.PubMedCrossRef

55.

Fazylov R, Soto E, Cohen S. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644–7.PubMedCrossRef

56.

Gniuli D, Leccesi L, Guidone C, et al. Thyroid function and insulin sensitivity before and after bilio-pancreatic diversion. Obes Surg. 2010;20:61–8.PubMedCrossRef

57.

Rubio IGS, Galrão AL, Santo MA, et al. Levothyroxine absorption in morbidly obese patients before and after Roux-en-Y gastric bypass (RYGB) surgery. Obes Surg. 2012;22:253–8.PubMedCrossRef

58.

Lizer MH, Papageorgeon H, Glembot TM. Nutritional and pharmacologic challenges in the bariatric surgery patient. Obes Surg. 2010;20:1654–9.PubMedCrossRef

Title: Influence of Bariatric Surgery on the Use and Pharmacokinetics of Some Major Drug Classes
Authors: Jan Peter Yska
Susanne van der Linde
Véronique V. Tapper
Jan A. Apers
Marloes Emous
Erik R. Totté
Bob Wilffert
Eric N. van Roon
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Obesity Surgery / Issue 6/2013
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-013-0882-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Influence of Bariatric Surgery on the Use and Pharmacokinetics of Some Major Drug Classes

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m2: A Surgeon’s Perspective

Metabolic Surgery for Type 2 Diabetes with BMI <35 kg/m2

Weight Loss and Weight Regain—5-Year Follow-Up for Circular- vs. Linear-Stapled Gastrojejunostomy in Laparoscopic Roux-en-Y Gastric Bypass

Prevalence and Risk Factors of Urinary Incontinence and Bladder Retention in Gastric Bypass Surgery: a Cross-Sectional Study

Dumping Syndrome Following Gastric Bypass: Validation of the Dumping Symptom Rating Scale

Author Response to Editorial on Routine Screening for Sleep Apnea